

Kyla A Mckay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740981/publications.pdf>

Version: 2024-02-01

34
papers

1,288
citations

393982

19
h-index

377514

34
g-index

35
all docs

35
docs citations

35
times ranked

1777
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1051-1059. | 1.4 | 29 |
| 2 | Administrative data for observational research in multiple sclerosis: Opportunities and challenges. <i>Multiple Sclerosis Journal</i> , 2022, 28, 3-6. | 1.4 | 2 |
| 3 | Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. <i>Annals of Neurology</i> , 2022, 91, 417-423. | 2.8 | 8 |
| 4 | Military service and related risk factors for amyotrophic lateral sclerosis. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 39-50. | 1.0 | 19 |
| 5 | Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153. | | 0 |
| 6 | Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 478. | 4.5 | 15 |
| 7 | Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686. | 1.0 | 4 |
| 8 | Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study. <i>Scientific Reports</i> , 2021, 11, 18528. | 1.6 | 5 |
| 9 | Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. <i>JAMA Network Open</i> , 2021, 4, e2136697. | 2.8 | 5 |
| 10 | Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, . | 3.1 | 22 |
| 11 | Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. <i>Neurology</i> , 2020, 94, e932-e941. | 1.5 | 20 |
| 12 | Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1028. | 4.5 | 68 |
| 13 | Long-term disability progression of pediatric-onset multiple sclerosis. <i>Neurology</i> , 2019, 92, e2764-e2773. | 1.5 | 69 |
| 14 | Disability worsening among persons with multiple sclerosis and depression. <i>Neurology</i> , 2019, 93, e2216-e2223. | 1.5 | 63 |
| 15 | Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. <i>Journal of Neurology</i> , 2019, 266, 481-486. | 1.8 | 13 |
| 16 | Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011â€“2016). <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 169-177. | 0.9 | 43 |
| 17 | Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1316-e1323. | 1.5 | 136 |
| 18 | Drug exposure and the risk of multiple sclerosis: A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 133-139. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 76-84. | 0.4 | 35 |
| 20 | Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018, 51, 1-10. | 1.1 | 18 |
| 21 | Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. <i>NeuroToxicology</i> , 2017, 61, 189-212. | 1.4 | 83 |
| 22 | Determinants of neurological disease: Synthesis of systematic reviews. <i>NeuroToxicology</i> , 2017, 61, 266-289. | 1.4 | 22 |
| 23 | Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017, 48, 124-130. | 1.1 | 6 |
| 24 | Comorbidity increases the risk of relapse in multiple sclerosis. <i>Neurology</i> , 2017, 89, 2455-2461. | 1.5 | 77 |
| 25 | Genetic variation associated with the occurrence and progression of neurological disorders. <i>NeuroToxicology</i> , 2017, 61, 243-264. | 1.4 | 18 |
| 26 | Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 588-596. | 1.4 | 44 |
| 27 | A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. <i>European Journal of Neurology</i> , 2016, 23, 1093-1100. | 1.7 | 29 |
| 28 | Health-related quality of life in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1417-1424. | 1.5 | 156 |
| 29 | Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 53-65. | 0.9 | 77 |
| 30 | Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 685-693. | 1.4 | 27 |
| 31 | Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 96-104. | 0.4 | 38 |
| 32 | Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. <i>BioMed Research International</i> , 2015, 2015, 1-11. | 0.9 | 76 |
| 33 | The systematic search for risk factors in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 237-238. | 4.9 | 7 |
| 34 | Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 470-476. | 0.9 | 40 |